体外诊断产品开发商Pillar Biosciences筹集了3450万美元融资-动脉网

Pillar Biosciences Raises $34.5M in Funding

CISION 等信源发布 2025-05-27 22:15



可切换为仅中文







NATICK, Mass.

马萨诸塞州内蒂克

，

May 27, 2025

2025年5月27日

/PRNewswire/ --

Pillar Biosciences, Inc

柱状生物科学公司

., the leader in Decision Medicine™, today announced they have finalized

决策医学™领域的领导者今天宣布他们已经最终确定

$34.5M

3450万美元

in funding, including a strategic investment from

在融资方面，包括来自

Illumina

因美纳

, structured financing from Soleus Capital and investments from existing investors.

，来自Soleus Capital的结构化融资以及现有投资者的投资。

Proceeds from this financing will be leveraged to advance Pillar's commercial activities including headcount and infrastructure to support biopharma partnerships and expand adoption of its distributable clinical testing kits.

此次融资的收益将被用来推动Pillar的商业活动，包括增加员工人数和基础设施，以支持生物制药合作伙伴关系，并扩大其可分发临床测试套件的采用。

'We are very pleased with our commercial growth over the past few years,' said Gang Song, Founder and Executive Chairman of Pillar Biosciences. 'We look forward to using this latest capital infusion to drive additional top-line growth as we move closer towards profitability.'

“我们对公司过去几年的商业增长感到非常满意，” Pillar Biosciences创始人兼执行主席宋钢表示，“我们期待利用这笔最新的资金注入来推动更多的营收增长，因为我们正朝着盈利的目标迈进。”

The financial investment by Illumina further reinforces its strong partnership with Pillar which includes previous agreements announced in

Illumina的金融投资进一步加强了其与Pillar的强有力合作伙伴关系，其中包含之前宣布的协议

2017

and

和

2023

。

'Pillar Biosciences has become an important strategic partner to enable Illumina to provide an expanded menu of research and clinical NGS solutions, accelerating access to precision oncology,' ' said

“Pillar Biosciences 已成为 Illumina 的重要战略合作伙伴，助力其提供更广泛的研究和临床 NGS 解决方案，加速精准肿瘤学的可及性，”

Ashley Van Zeeland

艾希莉·范·泽兰德

, vice president of Corporate Development Illumina. 'Pillar's rapid NGS targeted sequencing panels alongside Illumina's state-of-the-art sequencing and bioinformatics solutions delivers rapid, cost-effective genomic profiling of tumors, which is critical to advancing personalized therapy globally.'

，Illumina公司发展副总裁。“Pillar的快速NGS靶向测序面板与Illumina最先进的测序和生物信息学解决方案相结合，提供了快速且经济高效的肿瘤基因组分析，这对推动全球个性化治疗至关重要。”

'Access to rapid NGS testing solutions is critical to advancing precision medicine in oncology. We see Pillar's technology as a market leader, helping laboratories across the globe more effectively streamline and consolidate their molecular testing platforms, enabling faster time to results,' said .

“获得快速的NGS检测解决方案对于推动肿瘤学精准医疗至关重要。我们认为Pillar的技术是市场领导者，有助于全球各地的实验室更有效地简化和整合其分子检测平台，从而实现更快速的结果产出，”他表示。

Benjamin Lund

本杰明·伦德

from Soleus Capital. 'Pillar has demonstrated strong commercial growth over the past few years, including multiple biopharma collaborations.'

来自Soleus Capital。‘Pillar在过去几年中展现了强劲的商业增长，包括与多家生物制药公司的合作。’

About Pillar Biosciences

关于支柱生物科学

Pillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring.

Pillar Biosciences 是决策医学™ 的领导者，决策医学™ 是利用高准确性和高灵敏度的下一代测序 (NGS) 检测技术生成数据，从而优化癌症患者从肿瘤分析到治疗选择和复发监测的精准治疗选择。

Pillar's NGS testing solutions are powered by its proprietary SLIMamp® and PiVAT® technologies, helping to localize the testing process, reduce diagnostic costs and improve access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally. The company has more than 20 NGS testing kits available in IVD or RUO formats, with multiple panels in various stages of development.

Pillar公司的NGS检测解决方案由其专有的SLIMamp®和PiVAT®技术支持，有助于本地化检测流程，降低诊断成本，并提高全球临床医生、处方医生和患者对复杂NGS检测的可及性与效率。该公司提供20多种NGS检测试剂盒，适用于IVD或RUO格式，并有多个检测组合处于不同开发阶段。

Pillar Biosciences has operations in .

Pillar Biosciences 的运营地点在。

Natick, MA.

马萨诸塞州内蒂克。

For more information visit

更多信息请访问

pillarbiosci.com

and connect with us on

并关注我们

领英

。